Clin Pharmacokinet. 2021 Oct 07; doi: 10.1007/s40262-021-01068-0. Epub 2021 Oct 07.

Pharmacokinetic/Pharmacodynamic Modelling of Allopurinol, its Active Metabolite Oxypurinol, and Biomarkers Hypoxanthine, Xanthine and Uric Acid in Hypoxic-Ischemic Encephalopathy Neonates.

Clinical pharmacokinetics

Wan-Yu Chu, Kim V Annink, A Laura Nijstad, Christian A Maiwald, Michael Schroth, Loubna El Bakkali, Frank van Bel, Manon J N L Benders, Mirjam M van Weissenbruch, Anja Hagen, Axel R Franz, Thomas P C Dorlo, Karel Allegaert, Alwin D R Huitema,

PMID: 34617261 DOI: 10.1007/s40262-021-01068-0

Abstract

BACKGROUND: Allopurinol, an xanthine oxidase (XO) inhibitor, is a promising intervention that may provide neuroprotection for neonates with hypoxic-ischemic encephalopathy (HIE). Currently, a double-blind, placebo-controlled study (ALBINO, NCT03162653) is investigating the neuroprotective effect of allopurinol in HIE neonates.

OBJECTIVE: The aim of the current study was to establish the pharmacokinetics (PK) of allopurinol and oxypurinol, and the pharmacodynamics (PD) of both compounds on hypoxanthine, xanthine, and uric acid in HIE neonates. The dosage used and the effect of allopurinol in this population, either or not undergoing therapeutic hypothermia (TH), were evaluated.

METHODS: Forty-six neonates from the ALBINO study and two historical clinical studies were included. All doses were administered on the first day of life. In the ALBINO study (n = 20), neonates received a first dose of allopurinol 20 mg/kg, and, in the case of TH (n = 13), a second dose of allopurinol 10 mg/kg. In the historical cohorts (n = 26), neonates (all without TH) received two doses of allopurinol 20 mg/kg in total. Allopurinol and oxypurinol population PK, and their effects on inhibiting conversions of hypoxanthine and xanthine to uric acid, were assessed using nonlinear mixed-effects modelling.

RESULTS: Allopurinol and oxypurinol PK were described by two sequential one-compartment models with an autoinhibition effect on allopurinol metabolism by oxypurinol. For allopurinol, clearance (CL) was 0.83 L/h (95% confidence interval [CI] 0.62-1.09) and volume of distribution (V

CONCLUSION: The PK and PD of allopurinol, oxypurinol, hypoxanthine, xanthine, and uric acid in neonates with HIE were described. The dosing regimen applied in the ALBINO trial leads to the targeted XO inhibition in neonates treated with or without TH.

© 2021. The Author(s).

References

1. Lee ACC, Kozuki N, Blencowe H, Vos T, Bahalim A, Darmstadt GL, et al. Intrapartum-related neonatal encephalopathy incidence and impairment at regional and global levels for 2010 with trends from 1990. Pediatr Res. 2013;74:50–72. - PubMed
2. Azzopardi DV, Strohm B, Edwards AD, Dyet L, Halliday HL, Juszczak E, et al. Moderate hypothermia to treat perinatal asphyxial encephalopathy. N Engl J Med. 2009;361:1349–58. - PubMed
3. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database Syst Rev. 2013;1:CD003311. - PubMed
4. Azzopardi D, Strohm B, Marlow N, Brocklehurst P, Deierl A, Eddama O, et al. Effects of hypothermia for perinatal asphyxia on childhood outcomes. N Engl J Med. 2014;371:140–9. - PubMed
5. Webster D. Neonatal brain injury. Neonatal Intensive Care Nurs. 2019;351:351–74. - PubMed
6. Allen KA, Brandon DH. Hypoxic ischemic encephalopathy: pathophysiology and experimental treatments. Newborn Infant Nurs Rev. 2011;11:125–33. - PubMed
7. Epstein FH, McCord JM. Oxygen-derived free radicals in postischemic tissue injury. N Engl J Med. 1985;312:159–63. - PubMed
8. van Bel FV, Groenendaal F. Drugs for neuroprotection after birth asphyxia: pharmacologic adjuncts to hypothermia. Semin Perinatol. 2016;40:152–9. - PubMed
9. Palmer C, Vannucci RC, Towfighi J. Reduction of perinatal hypoxic-ischemic brain damage with allopurinol. Pediatr Res. 1990;27:332–6. - PubMed
10. Warner DS, Sheng H, Batinić-Haberle I. Oxidants, antioxidants and the ischemic brain. J Exp Biol. 2004;207:3221–31. - PubMed
11. Moorhouse PC, Grootveld M, Halliwell B, Quinlan JG, Gutteridge JMC. Allopurinol and oxypurinol are hydroxyl radical scavengers. FEBS Lett. 1987;213:23–8. - PubMed
12. Shadid M, Buonocore G, Groenendaal F, Moison R, Ferrali M, Berger HM, et al. Effect of deferoxamine and allopurinol on non-protein-bound iron concentrations in plasma and cortical brain tissue of newborn lambs following hypoxia-ischemia. Neurosci Lett. 1998;248:5–8. - PubMed
13. Boda D. Results of and further prevention of hypoxic fetal brain damage by inhibition of xanthine oxidase enzyme with allopurinol. J Perinat Med. 2011;39:441–4. - PubMed
14. Marro PJ, Mishra OP, Delivoria-Papadopoulos M. Effect of allopurinol on brain adenosine levels during hypoxia in newborn piglets. Brain Res. 2006;1073–1074:444–50. - PubMed
15. Annink KV, Franz AR, Derks JB, Rüdiger M, van Bel F, Benders MJNL. Allopurinol: old drug, new indication in neonates? Curr Pharm Des. 2018;23:5935–42. - PubMed
16. Maiwald CA, Annink KV, Rüdiger M, Benders MJNL, Van Bel F, Allegaert K, et al. Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): Study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III). BMC Pediatr. 2019;19:210. - PubMed
17. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet. 2007;46:623–44. - PubMed
18. Murrell GAC, Rapeport WG. Clinical pharmacokinetics of allopurinol. Clin Pharmacokinet. 1986;11:343–53. - PubMed
19. Mirzaei S, Taherpour AA, Mohamadi S. Mechanistic study of allopurinol oxidation using aldehyde oxidase, xanthine oxidase and cytochrome P450 enzymes. RSC Adv. 2016;6:109672–80. - PubMed
20. Wright DFB, Stamp LK, Merriman TR, Barclay ML, Duffull SB, Holford NHG. The population pharmacokinetics of allopurinol and oxypurinol in patients with gout. Eur J Clin Pharmacol. 2013;69:1411–21. - PubMed
21. Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol. 1999;48:501–9. - PubMed
22. Stocker SL, Mclachlan AJ, Savic RM, Kirkpatrick CM, Graham GG, Williams KM, et al. The pharmacokinetics of oxypurinol in people with gout. Br J Clin Pharmacol. 2012;74:477–89. - PubMed
23. Spector T. Oxypurinol as an inhibitor of xanthine oxidase-catalyzed production of superoxide radical. Biochem Pharmacol. 1988;37:349–52. - PubMed
24. Sierra H, Cordova M, Chen CSJ, Rajadhyaksha M. Confocal imaging-guided laser ablation of basal cell carcinomas: an ex vivo study. J Invest Dermatol. 2015;135:612–5. - PubMed
25. McGaurn SP, Davis LE, Krawczeniuk MM, Murphy JD, Jacobs ML, Norwood WI, et al. The pharmacokinetics of injectable allopurinol in newborns with the hypoplastic left heart syndrome. Pediatrics. 1994;94:820–3. - PubMed
26. van Kesteren C, Benders MJNL, Groenendaal F, Van Bel F, Ververs FFT, Rademaker CMA. Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia. Ther Drug Monit. 2006;28:339–44. - PubMed
27. Favié LMA, de Haan TR, Bijleveld YA, Rademaker CMA, Egberts TCG, Nuytemans DHGM, et al. Prediction of drug exposure in critically ill encephalopathic neonates treated with therapeutic hypothermia based on a pooled population pharmacokinetic analysis of seven drugs and five metabolites. Clin Pharmacol Ther. 2020;108:1098–106. - PubMed
28. Van Bel F, Shadid M, Moison RMW, Dorrepaal CA, Fontijn J, Monteiro L, et al. Effect of allopurinol on postasphyxial free radical formation, cerebral hemodynamics, and electrical brain activity. Pediatrics. 1998;101:185–93. - PubMed
29. Benders MJNL, Bos AF, Rademaker CMA, Rijken M, Torrance HL, Groenendaal F, et al. Early postnatal allopurinol does not improve short term outcome after severe birth asphyxia. Arch Dis Child Fetal Neonatal Ed. 2006;91:163–5. - PubMed
30. Peeters C, Hoelen D, Groenendaal F, Van Bel F, Bär D. Deferoxamine, allopurinol and oxypurinol are not neuroprotective after oxygen/glucose deprivation in an organotypic hippocampal model, lacking functional endothelial cells. Brain Res. 2003;963:72–80. - PubMed
31. Kim P, Yaksh TL, Romero SD, Sundt TM. Production of uric acid in cerebrospinal fluid after subarachnoid hemorrhage in dogs: Investigation of the possible role of xanthine oxidase in chronic vasospasm. Neurosurgery. 1987;21:39–44. - PubMed
32. Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72–9. - PubMed
33. West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science. 1997;276:122–6. - PubMed
34. Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, et al. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr Nephrol. 2009;24:67–76. - PubMed
35. Rosenkrantz TS, Hussain Z, Fitch RH. Sex differences in brain injury and repair in newborn infants: clinical evidence and biological mechanisms. Front Pediatr. 2019;7:211. - PubMed
36. Comets E, Brendel K, Mentré F. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the npde add-on package for R. Comput Methods Programs Biomed. 2008;90:154–66. - PubMed
37. Aoki Y, Nordgren R, Hooker AC. Preconditioning of nonlinear mixed effects models for stabilisation of variance-covariance matrix computations. AAPS J. 2016;18:505. - PubMed
38. Ueckert S, Karlsson MO, Hooker AC. Accelerating Monte Carlo power studies through parametric power estimation. J Pharmacokinet Pharmacodyn J Pharmacokinet Pharmacodyn. 2016;43:223–34. - PubMed
39. Dosne AG, Bergstrand M, Karlsson MO. An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn. 2017;44:509–20. - PubMed
40. Yang S, Roger J. Evaluations of Bayesian and maximum likelihood methods in PK models with below-quantification-limit data. Pharm Stat. 2010;9:313–30. - PubMed
41. Hande K, Reed E, Chabner B. Allopurinol kinetics. Clin Pharmacol Ther. 1978;23:598–605. - PubMed
42. Nelson DJ, Elion GB. Metabolic studies of high doses of allopurinol in humans. Adv Exp Med Biol. 1984;165 Pt A:167–70. - PubMed
43. Beedham C. Aldehyde oxidase; new approaches to old problems. Xenobiotica. 2020;50:34–50. - PubMed
44. Marro PJ, Baumgart S, Delivoria-Papadopoulos M, Zirin S, Corcoran L, McGaurn SP, et al. Purine metabolism and inhibition of xanthine oxidase in severely hypoxic neonates going onto extracorporeal membrane oxygenation. Pediatr Res. 1997;41:513–23. - PubMed
45. Elion GB, Yü TF, Gutman AB, Hitchings GH. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med. 1968;45:69–77. - PubMed
46. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, et al. Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature. 2002;417:447–52. - PubMed
47. Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos. 2005;33:1791–5. - PubMed
48. Breithaupt H, Tittel M. Kinetics of allopurinol after single intravenous and oral doses—noninteraction with benzbromarone and hydrochlorothiazide. Eur J Clin Pharmacol. 1982;22:77–84. - PubMed
49. Cheung KWK, van Groen BD, Spaans E, van Borselen MD, de Bruijn ACJM, Simons-Oosterhuis Y, et al. A comprehensive analysis of ontogeny of renal drug transporters: mRNA analyses, quantitative proteomics, and localization. Clin Pharmacol Ther. 2019;106:1083–92. - PubMed
50. Stiburkova B, Bleyer AJ. Changes in serum urate and urate excretion with age. Adv Chronic Kidney Dis. 2012;19(6):372–6. - PubMed

Publication Types

• Journal Article

Grant support

• 667224/H2020-PHC-2015-two-stage
• G0D0520N/iPREDICT project